MedPath
HSA Approval

SOFILEX FOR ORAL SUSPENSION 125 mg/5 ml

SIN10419P

SOFILEX FOR ORAL SUSPENSION 125 mg/5 ml

SOFILEX FOR ORAL SUSPENSION 125 mg/5 ml

November 16, 1998

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Regulatory Information

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Therapeutic

Prescription Only

Formulation Information

POWDER, FOR SUSPENSION

ORAL

Medical Information

J01DB01

cefalexin

Manufacturer Information

APEX PHARMA MARKETING PTE. LTD.

XEPA-SOUL PATTINSON (MALAYSIA) SDN BHD

Active Ingredients

CEPHALEXIN

125 mg/5 ml

Cephalexin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SOFILEX FOR ORAL SUSPENSION 125 mg/5 ml - HSA Approval | MedPath